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1. Introduction 
More than three decades after the discovery of Human Immunodeficiency Virus (HIV) as 
the causative agent of Acquired Immunodeficiency Syndrome (AIDS), a vaccine is still 
considered as the best hope for controlling the epidemic. In fact the history of medicine 
shows that no viral disease have ever been controlled without a vaccine.  
Remarkable success in the AIDS treatment has been achieved with the development of 
antiretroviral drugs that, by interfering with various aspects of the HIV life cycle, allowed 
an impressive control of infection (Fischl et al., 1987; Egger et al., 1997). The use of these 
drugs, however, was accompanied by new challenges related to side effects, high cost and 
resistance development (Carr, 2000; Hawkins, 2010; Menéndez-Arias, 2010; 
www.hivresourcetracking.org/treatments/vaccines). 
Antiretroviral treatment cannot prevent early infection events, such as transmission to sexual 
partners during the post-infection peak of viremia (Wawer et al., 1999) and the massive 
destruction of intestinal CD4+T cells during the first weeks of infection (Brenchley et al., 2004). 
Furthermore drugs delivery to poor and endemic areas is often hard due to practical 
limitations. In resource-limited countries only 1 out 4 HIV-positive individuals has access to 
antiretroviral medications, and for each person who begins the therapy, there are about 6 new 
infections (www.who.int/entity/hiv/mediacentre/universal_access_progress_report_en.pdf). 
These factors made difficult to control the pandemic through antiretroviral therapy.  
Others approaches could be taken in account to reduce HIV-1 infection in subjects at risk 
of exposure, including public health involvement (i.e.: screening of donor blood products), 
educational effort (i.e.: risk reduction counselling), or social imprinting (i.e.: male 
circumcision and behaviour modifications such as condom usage). In high seropositive 
communities, pre-exposure or post-exposure antiretroviral prophylaxis may reduce 
susceptibility to HIV infection, as well as the vertical HIV transmission from mother to 
child.  
The creation of an HIV-1 vaccine represents an unprecedented scientific challenge and it’s 
an absolute priority in field of HIV prevention. We must remember that vaccines are one of 
the most effective public health interventions ever known, but unfortunately, in HIV 
infection, the current perspective is that we will not have a product, even moderately 
effective, in the coming years.  
The truth is that often in the history of vaccinology it takes a long time since the discovery of 
infectious agents to the licensing of an effective vaccine (Heyward et al., 1998). This is due in 
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part to the fact that even today no one knows for sure how the immune system protects us 
against infections and, consequently, how to handle it for this to occur. In HIV/AIDS, the 
stimulation of a specific immune response is unlikely to immunize against HIV: there are no 
established immune correlates of protection (i.e.: humoral or cellular response), no 
documented cases of spontaneous recovery from AIDS or HIV infection, and no animal 
model that faithfully predicts HIV disease or vaccine responses in humans 
beyond the variability of the virus. Moreover HIV entries predominantly through mucosal 
surfaces, targets preferentially CD4+T cells, and rapidly establishes a persistent reservoir of 
latently infected cells, making difficult the study of the host/virus interaction as well as the 
development of an interventional strategy. 
Novel approaches for an HIV vaccination need a rational vaccine design, including a better 
integration of emerging scientific concepts and knowledge derived from vaccinology 
research fields. 
Models of natural resistance to HIV infection, including individuals able to control the 
infection (elite controllers) and some species of non-human primates, show that some level 
of control can be achieved (Dunham et al., 2006; Sumpter et al., 2007; Walker, 2007; 
Lederman et al., 2010; Poropatich & Sullivan, 2011).  
The creation of an effective HIV vaccine will require continued scientific research and 
cooperation between academic community and biotechnology industry with the 
contributions of brightest scientists, long-term commitments of stable and flexible 
funding, trials and vaccines accessibility for developing countries. In coming years, the 
prospect is that several area of scientific community will be involved seeking to combine 
the knowledge necessary to develop new strategies, new candidates and evaluating these 
products. 
This chapter will describe some aspects of the development of HIV vaccines, with emphasis 
on scientific efforts and challenges made to producing a safe and effective vaccine, strategies 
and methods used in the development of anti-HIV vaccines, current outlook and 
perspectives in this area. 
2. Major challenges to get an HIV vaccine 
Primary in prevention and control of infectious diseases, vaccines are a highly effective way 
to stimulate the immune system to fight pathogens. In the case of HIV infection, it has not 
yet been possible to obtain a vaccine to control infection, despite the efforts of the scientific 
community, the large financial investment and scientific and technological progress 
achieved. 
Considering the natural history of infection, an HIV vaccine has the principal aim to prevent 
the integration of HIV genetic material into the genome of the host cell in order to prevent 
systemic infection and the establishment of viral reservoirs. This occurs within a few days 
after exposure, when HIV rapidly replicates in the lymphoid tissues, so the window of 
opportunity to prevent the establishment of a persistent infection is very brief. Therefore an 
effective HIV vaccine should be able to activate the immune system against the virus very 
early after the infection. 
The complexity and diversity of HIV, its high capacity to evade the immune system and the 
missing gap in effective host immune response against the virus represent some major 
challenges to design an optimal vaccine. Moreover the absence of an experimental model 
able to mimic human infection represents another limit for pre-clinical studies. 
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2.1 HIV heterogeneity and cell targets 
HIV presents a genome of about 10,000 base pairs, composed of three structural genes (gag, 
pol and env) beyond the six accessory genes (vif,vpr, rev, tat,vpu and nef). The gag gene 
encodes the viral core protein as the capsid, matrix and nucleocapsid, pol encodes the viral 
enzymes (reverse transcriptase, protease, ribonuclease and integrase) and env gene encodes 
the envelope glycoproteins. Some products of these genes are targets of choice for the study 
of vaccines. 
The great genetic diversity of HIV represents a major obstacle to developing an effective 
vaccine. Such diversity is the result of a highly HIV replicative rate (new 1010 viral 
particles/day) and of its prone to errors retrotranscriptase (1 new nucleotide 
substitution/replication for a genome of approximately 10 000 bp). 
The highest degree of HIV diversity is found in the envelope glycoproteins. The amino acid 
sequences of Env may differ by about 15% between isolates of the same clade and in more 
than 35% between envelopes of different clades (Gaschen et al 2002).  
As a consequence of this high degree of mutational rate, HIV can counteract the selective 
pressure imposed by the host immune response, and it soon become able to evade an 
effective response. This aspect makes it difficult to identify potential HIV targets against 
which the immune system could be directed. 
Another important point is that an effective vaccine may protect against various HIV 
subtypes and clades prevalent in every region of the world. HIV is classified into two types: 
HIV-1 and HIV-2 that have a genetic homology around 40-50%. While HIV-2 is less 
pathogenic and its incidence is confined to Africa, HIV-1 is the causative agent of a 
worldwide pandemic. HIV-1 is divided into three groups M, O and N. The groups O and N 
are restricted to Central Africa, while group M is responsible for the AIDS pandemic. 
Within group M, HIV-1 isolates are divided into six subtypes and clades (A, B, C, D, E and 
G) and have distinct geographic distributions. While subtype B is prevalent in the 
Americas and Europe, subtype C, which accounts for more than 50% of AIDS cases 
worldwide, is prevalent in Southeast Asia and Africa. The difference between the amino 
acid sequences among viral clades differs by 20% and the variation within clades can 
reach over 10% in amino acid sequence. Furthermore, different subtypes may be 
associated with generating circulating recombinant forms (CRFs), further increasing the 
viral diversity. 
Another major challenge that hinders the design of an effective vaccine is the HIV tropism 
for immune cells. HIV uses the CD4 molecule as a receptor for cell entry. This molecule, in 
turn, is expressed mainly by T helper lymphocytes and to a lesser degree by dendritic cells, 
macrophages and monocytes. Since these are strategic cells within the immune system, the 
immune response in HIV-infected individuals is compromised (Figure1). 
Belonging to retroviruses, HIV integrates its genetic material into host cell genome. Days 
after infection the virus begins its haematogenous spreading from mucosal to lymphoid 
sites, particularly gut-associated lymphoid tissue (GALT) where a lot of CD4+ CCR5+ T 
memory lymphocytes are destructed (Matapallil et al., 2005).  
The massive loss of CD4+ T cells compromises the host immune response during  
the infection. Moreover, since the HIV genome is integrated latently until cells  
become activated, establishing viral reservoirs that hinder the complete elimination of 
infection. 
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Fig. 1. HIV cell target. HIV predominantly infects CD4+ lymphocytes, which play a 
fundamental role in the induction of specific immune response.  
APC: Antigen-presenting cell 
CTL: Cytotoxic T lymphocyte 
2.2 Host/virus interaction 
A key feature of the immune system is to "remember" and respond to antigens with which 
they've previously met. This property, called immunological memory, is the basis of the 
vaccination process. To play its role, a vaccine must therefore deliver the antigen to the 
immune system in order to stimulate it and to enable the development of memory. 
In this sense, a basic problem in developing an HIV vaccine is the lack of definition of the 
correlates of immune protection in HIV infection, so that is not completely clear what types 
of immune response should ideally be stimulated by vaccination and consequently what 
measure and criteria should be used to evaluate the effectiveness of the vaccine. 
Initially the first strategies implied to obtain an HIV vaccine were focused on inducing 
neutralizing antibodies against the viral envelope proteins (Dolin, 1995) and from mid-1990, 
studies began to focus on the activation of a cellular immune response.  
Stimulation of neutralizing antibodies with broad specificity for all HIV variants would be 
definitely interesting for a vaccine strategy. Evidence in nonhuman primates suggest that a 
protection could be afforded if neutralizing antibodies could be present in high 
concentration both in blood and mucosa at the time of first infection (Parren et al., 2001). 
However, the induction of neutralizing antibodies against HIV is hampered by some 
specific characteristics of the virus, such as 
a. The high epitopes mutation rate, which causes loss of recognition capacity by 
antibodies; 
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b. The large number of subtypes of HIV that exhibit little cross-reactivity;  
c. The high rate of glycosylation on the viral envelope  
d. The existence of hidden CD4/receptor binding sites which difficult the access of the 
antibodies. (Figure 2) 
 
 
Fig. 2. Sites of antibody binding to gp120. Neutralizing and non-neutralizing sites of gp120. 
The sites of glycosylation of the molecule are also shown. 
Considering that HIV infects CD4+ T cells, the stimulation of a cellular response is important 
for the destruction of infected cells by cytotoxic T lymphocytes (CTLs) before the release of 
new viral particles. Thus, in a context of an anti-HIV vaccine CD4+ T cells should be rapidly 
expanded to stimulate the right cytotoxic response against infected cells and drive memory 
cells to sites potentially susceptible to infection such as mucosal and lymph nodes.  
Although many studies provide strong evidence that a cellular response can effectively 
suppress HIV (Rowland-Jones et al., 1998; Hladik et al., 2003), it remains unclear how this 
viral suppression occurs and how a vaccine could stimulate it. Peculiar characteristics of the 
virus and the nature of infection hinder the development of an appropriate cellular 
response, for example,  
a. The reduction of the expression of MHC class I molecules mediated by the HIV Nef 
protein;  
b. The establishment and maintenance of latent viral reservoirs in cells 
c. The massive destruction of T cells specific or not for HIV, caused mainly by activation-
induced apoptosis. (Cadogan & Dalgleish, 2008). 
In this context, even though there are not clear evidences regarding the type of immune 
response to be induced by an HIV vaccine, it is reasonable to assume that elements of the 
immune response important to ensure a real effectiveness of an HIV vaccine may depend on 
both neutralizing antibody and specific cellular immunity, and besides, also on innate 
immunity. In a simplified view, neutralizing antibodies prevent the entry of virus into the 
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cell by blocking the transmission and infection, while the cellular response would act 
destroying HIV-infected cells before the release of new viral particles in order to control an 
yet established infection. 
Another interesting tips is that being mucosal the primary site of natural HIV infection 
(Kozlowski & Neutra, 2003) an effective vaccine must induce anti-HIV-1 neutralizing 
antibodies at mucosal surfaces to prevent the infection and cytotoxic T lymphocytes (CTLs) 
in sub-mucosal areas to kill virus-infected cells, or a combination of both. Unfortunately, the 
immune response within the mucosa may be associated with a high viral replication and 
dissemination: HIV activates and recruits a lot of target cells and the virus uptake by 
dendritic cells allow its dissemination to draining lymph nodes avoiding antibody 
recognition. The challenge to an effective vaccine is to activate mucosal immunity at the 
right time. Moreover, all mucosal vaccines have to overcome tolerance, which is related with 
regulatory cells and depend on the nature of the antigen, the dosage, the method of delivery 
and on whether or not adjuvant is used. 
2.3 Lack of animal models 
Actually there is no animal model capable of to mimic the human HIV infection and AIDS 
development. The use of animal models could help the investigation of disease pathogenesis 
and provide information about toxicity and efficacy of drugs and vaccines to reduce risk, 
duration and cost of a clinical trial.  
Despite its relatively low cost and ease of maintenance in animal houses, the use of small 
rodents as experimental models for HIV infection is not appropriate since HIV is unable to 
sustain infection in murine cells. More recently it has been demonstrated the use of 
humanized mice models (Van Duyne et al., 2009). 
Studies in non-human primates (NHP; i.e.: Macaca rhesus), when allowed, even if expensive, 
gave some good results and have the advantage of sharing a high genetic background with 
humans. NHP are the natural host of a retrovirus of the same HIV family, SIV (Simian 
Immunodeficiency Virus) which has a very low mutational rate compared to HIV. In some 
studies the SHIV, a hybrid virus composed of parts of the genome of HIV and SIV, has been 
implied to create the infection model (Stapransan et al, 2010). 
Although providing crucial information about viral immunobiology and vaccine design, it 
must be taken in account that important differences in the viral infection exist between 
humans and NHP. Data from NHP models should be critically evaluated for their predictive 
value in human trials (Shedlock et al., 2009).  
3. Strategies and methods used in the development of anti-HIV vaccines 
Like most vaccines, candidates for HIV vaccine contained weakened or killed forms of the 
virus or viral components which resembling original HIV and could be able to stimulate the 
immune system to develop an appropriate response. Taking in account all these 
considerations, in the past decades several aspects related to the vaccine composition, route 
of immunization and vaccine strategy have been tested in the effort to develop an effective 
HIV vaccine. 
3.1 Vaccine composition 
3.1.1 Immunogen production 
Many techniques have been employed in order to produce relevant immunogenic HIV 
antigens, such as: 
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 chemical (eg. alcohols) or heat inactivated virus particles; 
 viral proteins or peptides artificially synthesized (mimetopos) or produced by the 
insertion of relevant genes in biological vectors (recombinants); 
 proteins expressed in the form of virus like particles (VLP), consisting of structurally 
preserved viral epitopes (i.e.: parts of the virus surface proteins), without the viral 
genetic material, thus preventing their replication. 
 HIV genetic material to insert directly into cells that will express their products. Usually 
this material is inserted in the form of plasmids, which are molecules of extra-
chromosomal circular DNA, with independent replication. The insertion of genetic 
material in the body can be made directly (eg. electroporation or gene guns using 
compressed gas) or through biological vectors. 
Live attenuated virus vaccines have not been investigated in anti-HIV vaccines due to the 
risk of development of virulence, as evidenced in a model of NHP (Whatmore et al., 1995). 
 
 
Fig. 3. Immunogens used in the composition of HIV vaccines. There are three types of 
immunogens: whole vital particle, peptides or recombinant proteins and genetic material of 
the virus, which may or may not be inserted within vectors. Sometimes the combination of 
different immunogens can be used (prime-boost strategy). 
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The advantages and disadvantages of some types of immunogens used in the development 
of HIV vaccines are summarized in Table 1. 
 
PRODUCT ADVANTAGE DISADVANTAGE 
Inactivated 
virus 
- whole virus is included 
in the vaccine 
-risk that the preparation 
contains active virus 
- difficult to produce in large 
scale 
-the response induced by 
chance is directed only to the 
type of virus 
Peptide 
-production relatively 
simple and inexpensive 
-safe 
-un representative in terms 
of immunogenic epitopes 
Recombinant 
proteins 
-production relatively 
simple 
-safe 
-low immunogenic 
DNA 
-production relatively 
simple and inexpensive 
-there are gaps of knowledge 
about the integration of 
DNA in the human genome 
-low immunogenic 
Vaccines based 
on biological 
vectors 
-safe 
-it is possible to control 
the type and amount of 
HIV protein 
- limited ability to 
incorporate HIV genes (in 
the case of viral vectors) 
- limited immunogenicity by 
the existence of prior 
immunity to the vector 
- production platforms more 
complex (viral vectors) 
Table 1. Advantages and disadvantages of some types of immunogens used in the 
development of HIV vaccines 
3.1.2 Adjuvants  
A vaccine adjuvant is a component that potentiates the immune responses to an antigen 
and/or modulates it towards the desired immune responses (i.e.: with respect to 
immunoglobulin classes and induction of cytotoxic or helper T lymphocyte responses). In 
addition, certain adjuvants can be used to promote antibody responses at mucosal surfaces. 
Activation of innate immune system and in particular of dendritic cells (DCs) is a crucial 
mechanism by which adjuvants stimulate protective adaptive immunity against the 
vaccine antigen. 
As immune response is typically initiated by activation of antigen presenting cells (APCs), 
notably dendritic cells (DCs). There has been significant interest in improving APC-
stimulating adjuvants as a key step in constructing better vaccines 
Adjuvants have several forms, ranging from mineral salts such as alum to oil-based 
emulsions. Moreover molecular adjuvants such as proteins, lipids, nucleic acids, 
carbohydrates, or chemical compounds have a known receptor in DCs (i.e.: Toll Like 
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receptors - TLRs) and result in an improvement in the quantity or quality of the ensuing 
immune response (Kornbluth & Stone, 2006). 
 
CLASS EXAMPLE 
CD40 agonists 
CD40L or its derivates, Agonistic anti-CD40 
antibodies, Heat shock protein (Hsp70) 
NKT cell ligand CD1d-binding NKT 
TLRs agonists 
poly(I:C), LPS, and imidazoquinolines act on 
TLR3, TLR4, and TLR7 (mDCs) 
imidazoquinolines and CpG ODP act on TLR7 
and TLR9 (pDCs) 
flagellin act on TLR5 (Vassilieva et al., 2011) 
NLRs agonists 
MDP act on NOD2 and NALP3, extracellular 
ATP and pathogen RNA act on NALP3 
Chemokines MIP-1a, CCL19/EBI1-ligand and CCL21/SLC 
Table 2. Molecular adjuvants for HIV vaccine strategy. 
Many adjuvants have been developed in the past, but were never accepted for routine 
vaccination because of safety concerns (e.g. acute toxicity and the possibility of delayed side 
effects).  
3.2 Route of administration 
Vaccine delivery systems are the sum of pharmacologic technologies (including drug 
preparation, route of administration, site targeting, metabolism and toxicity) and have the 
principal aim to make the vaccine preparation faster and easier available to immune system. 
In its broadest sense, the concept of vaccine delivery systems can be expanded to include a 
diverse range of devices and physical delivery systems that are designed to improve the 
potency of vaccines or to allow immunization using novel, non-invasive routes (eg. gene-
gun approach, devices designed to fire powdered vaccines into the skin through the use of 
helium gas and vaccine patches). Delivery systems may function to improve antigen access 
to lymph nodes in a number of ways:  
a. increase antigens presenting cells (APCs), generally dendritic cells (DC), infiltration into 
the injection site; 
b. promote the uptake of antigen in APCs through activating phagocytosis; 
c. deliver antigen from the injection site to the local lymph node trough into the lymphatic 
system 
Various routes of HIV vaccine administration have been used starting from the most 
common (eg. subcutaneous, intramuscular) to more specific such as mucosal with different 
outcomes. HIV transmission occurs through mucosal (specially of the genital tract) and 
many efforts have been done to better characterize the mucosal associated lymphoid tissue 
(MALT) and its involvement in early HIV infection, with the final purpose to use the 
mucosal route of immunization. For vaccine design, the choice of mucosal inductive site is 
critical in determining the distal effector site to which induced memory cells will home. In 
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HIV vaccine research, many mucosal sites were chosen to administer the immunogen: nasal 
mucosal (Vajdy & Singh, 2006), intratracheal/aerosol vaccination (Corbett et al., 2008), oral 
vaccination (Stahl-Hennig et al., 2007, N. Cuburu et al., 2007), rectal/colonic vaccination 
(Belyakov et al., 2006), intravaginal vaccination- (Pialoux et al., 2008).  
3.3 Vaccination strategies 
The vaccination strategy comprehends the combination of diverse types of vaccine 
(immunogen, adjuvant, route of immunization) with different schedules to increasing the 
vaccine potential immunogenic effect. In HIV vaccine several combinations of immunogens 
(inactivated virus, viral proteins, recombinant viral DNA), routes and schedules have been 
tested to augment the delivery of HIV antigens to the immune system. 
For example, viral vectors are efficient to place HIV relevant epitopes within the target cells 
and, due to their composition, to stimulate the innate response, promoting an adjuvant 
effect, although it has been observed that the immunogenicity of these vectors could be 
affected by the competition between HIV and vector epitopes in the context of antigen 
presentation. For these reason it was developed the strategy to combined this type of 
vaccine with a vaccine based on HIV proteins or peptides in a such called prime-boost 
regimen. 
Prime-boost strategy was first time used in 1992 in NHP studies (Hu et al., 1992). Briefly, it 
consists in the administration of one type of vaccine, such as a live-vector vaccine, followed 
by or together with a second type of vaccine, such as a recombinant subunit vaccine. The 
intent of this combination regimen is to induce different types of immune responses and 
enhance the overall immune response, a result that may not occur if only one type of vaccine 
were to be given for all doses (Ranasinghe et al., 2009). 
3.4 Steps of vaccine development  
The development of a vaccine is a process that requires several steps aiming to answer 
specific questions and to test concepts through experimental practice. Scientific knowledge 
generated from the execution of each stage or phase will give useful data for planning the 
next step. 
The development of an effective vaccine against HIV infection, due to its unique aspects, 
will be an unprecedented challenge, and scientific rigor and discipline, statistical principles 
and bioethics should be required to achieve success.  
The preliminary step is to generate more ideas. Established scientists in universities, 
research institutes and industry use the existing scientific knowledge and technology to 
develop ideas of how a vaccine might work.  
From there, preclinical studies should be performed before human trials to assess whether a 
novel product has scientific merit to be a candidate vaccine. Such pre-clinical studies involve 
in vitro experiments and in vivo tests in available animal models to obtain information 
regarding the efficacy, toxicity and pharmacokinetics, using varying doses of the product 
being tested. 
The transformation process of a candidate product in a vaccine logarithmic increases the 
cost and complexity of the research, as it moves from laboratory to clinical application. It is 
also important to emphasize that only a small percentage of the candidate products being 
studied in preclinical development is considered safe and promising enough to be evaluated 
in humans (clinical phase). 
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Once proven its potential as a vaccine candidate, the clinical phase of the study will start 
to evaluate safety, immunogenicity and efficacy of the product. Phases I-III are required 
for licensing the product. In the process of vaccine development, clinical trials may last for 
many years and the number of volunteers is increasing at every step. The goals set for 
each stage involves pharmacological and clinical issues, evaluated in a progressive manner 
throughout the process (www.ich.org - General Considerations for Clinical Trials). 
The clinical trial itself begins in Phase I: the candidate vaccine is first evaluated in a small 
group of human volunteers in order to evaluate its safety, tolerability, pharmacokinetics and 
pharmacodynamics and identify possible side effects. 
In Phase I trial it is also possible to evaluate efficacy markers (e.g.: the generation of 
antibodies and/or cytotoxic T response), allowing a preliminary assessment of the ability of 
the vaccine to generate an immune response. Once the safety of the candidate product has 
been checked, the research could proceed to the next step (Phase II).  
The objective of Phase II is to test the candidate vaccine in a larger number of volunteers 
with two principal purposes: identify side effects related to the product use (within the 
perspective of future safety analysis, i.e.: toxicity) and collect preliminary indications of 
product potential effectiveness (efficacy). 
Sometimes these aims are studied in different moments and the Phase II trials are divided 
into: 
a. Phase IIa: designed to determine the optimal dose of vaccine (dose-response studies). 
b. Phase IIb: designed to study the vaccine efficacy. 
The Phase III trials are the last stage before possible licensing of the vaccine for marketing. 
They are randomized controlled trials, often multi-centric, involving large numbers of 
patients. The primary objective of this step is to evaluate the effectiveness of the product. 
Achieving a high level of effectiveness at this stage, however, does not necessarily guarantee 
that the product is effective in the general population, which will be evaluated in phase IV. 
Phase IV trials, also called post-evaluation of efficacy, are pharmacovigilance studies 
performed after licensing the product and that aim to measure the effect of the product in a 
population. The importance of this phase is to assess the real impact of a vaccine in the 
epidemic.  
The conduct of clinical trials involving prophylactic and therapeutic vaccines for HIV 
remains a challenge. In terms of design and implementing Phase I and early Phase II are 
relatively easy to do, although studies involving analysis of effectiveness show a higher 
degree of complexity. For prophylactic vaccines, the statistical requirements to demonstrate 
a real prevention of infection require a very large number of patients and they are 
sometimes prohibitive. Clinical trials for HIV vaccines require the appropriate preclinical 
studies and the development of better laboratory markers of efficacy. 
The role of society is essential for the success of all the program to develop HIV vaccines 
and the establishment of a genuine dialogue with the community facilitates clinical research 
with HIV vaccines. 
4. Current outlook 
Obtaining an HIV vaccine has been one of the biggest challenges of this century. To date 
numerous clinical trials have been conducted to test candidate products as prophylactic 
vaccine.  
www.intechopen.com
 Recent Translational Research in HIV/AIDS 
 
482 
Most initial approaches have focused on the gp120 HIV envelope protein. At least thirteen 
different gp120 candidates have been evaluated in Phase I trials in the USA predominantly 
through the AIDS Vaccine Evaluation Group, showing to be safe and immunogenic in 
diverse populations. They have induced neutralizing antibody, but rarely induced CD8+ 
cytotoxic T lymphocytes (CTL). Moreover it was very difficult to induce and maintain the 
high anti-gp120 antibody titers necessary to have any hope of neutralizing an HIV exposure. 
The availability of several recombinant vectors (adenovirus, canarypox) carrying HIV gens 
(gag, pol, nef or env) has provided interesting results characterized principally by a poly-
functional CTL responses. 
Currently, about 20 clinical trials are underway, most protocols for Phase I. 
 
PROTOCOL SPONSOR PRODUCT N 
TRIAL 
SITE 
fase 
HVTN 082 NIAID, HVTN 
VRC-HIVDNA016-00-VP; VRC-
HIVADV014-00-VP 
 USA I 
PedVacc001 & 
PedVacc002 
Medical Research Council MVA.HIVA 48 Kenya I 
HVTN 078 NIAID, EuroVacc, HVTN 
NYVAC-B; VRC-HIVADV038-00-
VP 
80 
Switer
zland 
I/II 
HVTN 505 NIAID, HVTN 
VRC-HIVDNA016-00-VP; VRC-
HIVADV014-00-VP 
Prime: VRC-HIVDNA016-00-VP 
1,350 US II 
B001 
IAVI, University of 
Rochester Medical Center 
Adenovirus serotype 35 vector. 
Ad35-GRIN/ENV consists of two 
vectors: Ad35-GRIN vector with 
gag, reverse transcriptase, integrase, 
and nefAd35-ENV vector with 
gp140 env 
42 USA I 
HIVIS 05 
Swedish Institute for 
Infectious disease Control 
MVA-CMDR 24 
Swede
n 
I 
P001 
IAVI, Indian Council of 
Medical Research, 
Tuberculosis Research 
Centre, Chennai; National 
AIDS Research Institute, 
Pune 
Prime: ADVAX (DNA vaccine 
containing env, gag, pol, nef and 
tat) 
Boost: TBC-M4 (MVA vector with 
env, gag, RT, rev, tat and nef) 
32 India I 
Tiantianvaccinia 
HIV 
Vaccine 
Chinese Center for Disease 
Control and Prevention, 
National Vaccine and 
SerumInstitute, Peking 
Union Medical College 
HIV-1 CN54 gag, pol and env genes 
with DNA and rTV vectors 
80 China I 
Ad5HVR48.EN
VA.01 
NIAID, Brigham and 
Women’s Hospital 
Recombinant Adenovirus HIV-1 
Vaccine, Ad5HVR48.ENVA.01 
48 USA I 
HVTN205 GeoVax, HVTN 
Prime: DNA vaccine containing 
gag, pol, env, rat,rev, vpu 
Boost: MVA vaccine containing 
gag, pol, env 
225 
USA, 
Peru 
II 
HVTN 073 
HVTN, SAAVI, Brigham and 
Women’s Hospital CRS, 
Fenway Community Health,
Clinical Research Boston, 
Prime: SAAVI DNA-C2 
Boost: SAAVI MVA-C; DNA 
plasmid vaccine with gag, RT, tat, 
nef, env 
48 
USA, 
South 
Africa 
I 
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PROTOCOL SPONSOR PRODUCT N 
TRIAL 
SITE 
fase 
Crossroads, Chris Hani 
BaragwanathHospita 
VRC 015 (08-1-
0171) 
NIAID, VRC, NIH Clinical 
Center 
Multiclade Recombinant HIV-1 
Adenoviral Vector Vaccine, 
VRCHIVADV014-00-VP 
40 USA I 
Ad26.ENVA.01 
NIAID, IPCAVD, Brigham 
and Women’s Hospital, Beth 
Israel Deaconess Medical 
Center, Crucell
Recombinant adenovirus serotype 
26 (rAd26) vaccine 
48 USA I 
NCHECR-AE1 
NCHECR, University of 
New South Wales, Thai Red 
Cross AIDS Research Centre
A candidate prophylactic DNA 
prime-rFPV boost HIV vaccination 
strategy (rFPV-HIV-AE;pHIS-HIV-
AE) 
8 
Thaila
nd 
I/II 
VRC 012 NIAID, VRC 
HIV-1 adenovirus vector vaccine 
VRC-HIVADV027-00VP: dose 
escalation and prime-boost with an 
HIV-1 adenovirus vector 
vaccine, VRC-HIVADV038-00-VP 
35 USA I 
HVTN 077 
NIAID, HVTN, Alabama 
Vaccine, San Francisco 
Vaccine and Prevention, 
Hope Clinic of the Emory 
Vaccine Center, NY Blood 
Ctr./Union Square, NY 
Blood Ctr./Bronx, 
University of Rochester 
HVTN
Recombinant Adenoviral Subtype 
35 (rAd35) and Subtype 5 (rAd5) 
HIV-1 Vaccines When Given as a 
Heterologous Prime-Boost Regimen 
or as Boosts to a Recombinant DNA 
Vaccine in Healthy, Ad5-Naïve and 
Ad5-Exposed (VRC-HIVDNA044-
00-VP;VRC-HIVADV027-00-
VP;VRC-HIVADV038-00-VP)
192 USA I 
HPTN 027 
HVTN, International 
Maternal Pediatric 
Adolescent AIDS Clinical 
Trials Group,Makerere 
University, Johns Hopkins 
University, Mulago Hospital, 
Sanofi-Pasteur
Canarypox viral vector with 
envandgag-pol 
50 
Ugand
a 
I 
HVRF-380- 
131004 
Moscow Institute of 
Immunology, 
FederalMedical and 
Biological Agency, Russian 
Federation Ministry of 
Education and Science
VICHREPOL with polyoxidonium 
adjuvant 
15 Russia I 
RV 138; B011 
Walter Reed Army Institute 
of Research, US Military HIV
Sanofi Pasteur Live Recombinant 
ALVAC-HIV (vCP205, HIV-1 
Env/Gag/Pol) subcutaneously, 
intradermally, or intramuscularly
36 USA I 
EnvDNA 
St. Jude’s Children’s 
Research Hospital
Recombinant HIV-1 multi-envelope 
DNA plasmid vaccine with env
6 USA I 
RV 156A 
NIAID, HVTN, VRC, 
MHRP, Makerere U. 
VRC-HIVADV014-00-VP alone or 
as a boost to VRCHIVDNA009-00-
VP
30 
Ugand
a 
I 
Table 3. Ongoing clinical trials (www.avac.org/ht/a/GetDocumentAction/i/3436). 
The results of Phase II and Phase III major prophylactic trials are summarized above. 
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4.1 VAX 004 trial (Phase III, USA 1998-2002) 
The phase III VAX 004 trial enrolled 5,403 USA participants between 1998 and 1999. 
Volunteers received 7 injections of either vaccine or placebo (ratio, 2:1) over 30 months. 
The study vaccine contained 2 rgp120 HIV-1 envelope antigens (300 mg each of two 
recombinant proteins rgp120/HIV-1 MN and GNE8) (AIDSVAX B/B; VaxGen) that had 
been derived from 2 different subtype B strains and that were adsorbed onto 600 mg of 
alum. GNE8 gp120 was cloned directly from peripheral-blood mononuclear cells and had 
the CCR5 phenotype; the GNE8 gp120 DNA sequence was deposited in GenBank. 
The vaccine did not prevent HIV-1 acquisition and there was no overall protective effect 
(Flynn et al., 2005). 
4.2 STEP trial (Phase II, USA, 2004-2007) 
On December 13, 2004, the HIV Vaccine Trials Network (HVTN) began recruiting for the 
STEP study, a 3,000-participant phase II clinical trial of a novel HIV vaccine, at sites in North 
America, South America, the Caribbean and Australia.  
The trial was co-funded by the National Institute of Allergy and Infectious Diseases 
(NIAID/NIH, USA), and the pharmaceutical company Merck & Co. Merck developed the 
experimental vaccine called V520 which contains a adenoviral vector rAd5 carrying three 
subtype B HIV genes (gag/pol/nef). The vaccine was administered in prime-boost regimen 
at 0, 1 and 6 months. The follow up of vaccinated subjects showed the lack of efficacy of this 
vaccine, as well as an increment in HIV-1 infection in individuals with prior immunity to 
adenovirus. Adenovirus vectors and many other viral vectors currently used in HIV 
vaccines, will induce a rapid memory immune response against the vector. This results in an 
impediment to the development of a T cell response against the inserted antigen. 
For this reason the phase II trial was closed in September 2007 and other vaccine protocols 
in progress including the same vector vaccine such as the HVTN503 (Phambili) were 
cancelled or modificated (Barouch & Korber, 2010). 
While the final results of STEP have been disappointing, this study has raised its 
contribution to redefine the priorities in HIV vaccines research field, demonstrating the need 
to focus on basic research, preclinical and clinical studies. 
4.3 RV144 trial (Phase III, Thailand, 2003-2009) 
The phase III HIV vaccine RV144 involved more than 16,000 young Thailandese adults at 
variable risk for infection between October 2003 and September 2009. Ever six months, 
volunteers received a prime-boost vaccination including six injections of a vaccine called 
ALVAC-HIV (vCP1521, Sanofi Pasteur) with the last two of the six injections being a 
combination of that vaccine and another one called AIDSVAX B/E (gp120, Genentech).  
ALVACHIV consists of a viral vector containing genetically engineered versions of three 
HIV genes (env, gag and pro).The ALVAC vector is an inert form of canarypox, a bird virus 
which cannot cause disease or replicate in humans. AIDSVAX B/E is composed of 
genetically engineered gp120. The RV 144 protocol was sponsored by the Surgeon General 
of the United States Army and conducted by the Thailand Ministry of Public Health with 
support from the United States Army Medical Research and Materiel Command and the 
NIAD/NIH.  
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The rate of HIV infection among volunteers who received the experimental vaccine being 
tested in the trial was 31% lower than the rate of HIV infection among volunteers who 
received placebo (Rerks-Ngarm et al., 2009). 
Although showing only a modest benefit, this work has renewed optimism in this field of 
research. However, criticisms related primarily to the study design and statistical method 
employed to analyse data generated debate about the results (Cohen, 2009; Letvin, 2009). 
4.4 Dendritic cell based immunotreatment 
In addition to trials aimed at obtaining prophylactic HIV vaccine, has been also developed 
protocols for therapeutic vaccination using dendritic cells (DC) for the treatment of 
individuals already infected with HIV. 
DCs are potent antigen presenting cells that act as controllers and regulators of the immune 
system and are the only cells capable of fully activate naive CD4 lymphocytes and thus 
initiate a specific response (Banchereau & Steinman, 1998). In the context of an HIV vaccine  
 
 
 
Fig. 4. Treatment of HIV infected patients with monocyte-derived DCs. Peripheral blood 
mononuclear cells (PBMC) are obtained by leukapheresis and monocytes are separated and 
cultured in the presence of IL-4 and GM-CSF to obtain immature DCs (iDCs). iDCs are 
loaded with the antigen of interest and are activated by different stimuli for maturation. 
Mature DCs (MDCs), potentially able to migrate and to present antigens, are reinoculate 
into the patient. 
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AUTHORS n 
TYPE OF 
ANTIGEN 
IMMUNOGENICITY 
ASSESSMENT 
Kundu et 
al., 1998 
6 
Recombinant HIV-1 
MN gp160 or HLA-
A2-restricted 
synthetic peptides 
of envelope, Gag, 
and Pol 
Envelope-specific CTL- and 
lymphocyte-proliferative 
responses, IFN-gamma and IL-
2 production, peptide-specific 
lymphocyte-proliferative 
responses 
Lu W et al., 
2004 
18 
Chemically inactivated 
autologous HIV-1 
Serum 
neutralizingantibodytiters, 
HIV-1-specific interferon-γ (IFN-γ) 
expressing CD4+ T and CD8+ cells, 
HIV-1-specific IL-2- expressing 
CD4+ T cells, HIV-1 gag−specific 
CD8+ T cells, HIV-1 gag−specific 
CD8+ T cells expressing perforin 
Garcia F et 
al.,2005 
12 
Heat-inactivated 
autologous human 
immunodeficiency 
virus type 1 (HIV-1) 
Lymphoproliferation, 
Th1 cell levels, cytotoxic T 
lymphocyte [CTL] levels, 
serum 
neutralizingantibodytiters and 
changes in lymphoid tissue 
Ide F et al., 
2006 
4 
HIV-1-derived 
cytotoxic T 
lymphocytes (CTL) 
peptides 
 
IFN-g production in CD8 
lymphocytes 
Connolly 
NC et al., 
2008 
18 
Gag, Env, and Pol 
peptides 
Gamma interferon (IFN-)-
producing cells (PBMC) 
 
Ghandhi 
RT et al., 
2009 
29 
Viral vector 
(canarypox) 
expressing HIV-1 
envandgag and a 
synthetic 
polypeptide 
encompassing 
epitopes from 
nefandpol 
Gamma interferon (IFN-)-
producing cells (PBMC), 
lymphocyte-proliferative 
responses 
Garcia F et 
al, 2011 
24 
Heat-inactivated 
autologous human 
immunodeficiency 
virus type 1 (HIV-1) 
Lymphoproliferation, serum 
neutralizing antibody titers, 
ELISPOT 
Table 4. Parameters used in the post-vaccine immune response assessment  
HLA= Human Leukocyte Antigen. IL-2= Interleukin-2 . PBMCs=Peripheral Blood 
Mononuclear Cells. 
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becomes desirable to induce a specific and effective activation of the immune system against 
the viral chronic infection. 
Protocols of immunotherapy with DCs began in the late 1990 and since then a growing 
number of studies evaluating this strategy. Because it is an individualized protocol, the 
number of individuals in the tests is always limited, never exceeding a few tens of 
individuals. 
It is a strategy that involves the collection of mononuclear cells from HIV-infected 
individual, separation of monocytes and stimulation of these cells with cytokines to 
differentiate into immature dendritic cells. Dendritic cells are then sensitized (pulsed or 
loaded) with the antigen of interest, activated and reinoculated into the individuals (Figure 
4). The objective of this strategy is to stimulate the immune response by enhancing antigen 
presentation mediated by dendritic cells. 
An overview of the works conducted so far (Table 4) shows although that the products are 
always safe and the results are quite heterogeneous (Kundu et al., 1998; García et al., 2005, 
2011; Ide at al., 2006; Connolly et al., 2008, Lu et al., 2004, Ghandhi, 2009)  
Considering the difficulty to obtain an HIV prophylactic vaccine, the immunotherapy offers 
a unique opportunity to study the mechanisms of immune response against the virus and 
contribute to the definition of correlates of protection in HIV infection. Knowledge 
generated from studies of DC-based immunotherapy may contribute also to the 
development of prophylactic vaccines. 
5. Conclusions 
Despite numerous difficulties and great scientific challenges that must be overcome to 
obtain an HIV vaccine, the extraordinary advance in biomedical research and the 
remarkable progress achieved show clear reasons for optimism. 
Knowledge has been accumulated on the biology and diversity of HIV; new methods have 
been used for the production of immunologically relevant antigens; the study of immune 
response in exposed not-infected individuals and in elite controllers has generated 
important information regarding the type of effective immune response against HIV. 
Furthermore, immunotherapy protocols in infected individuals provide a unique 
opportunity to studying immune mechanisms against the virus. 
Lessons from the failure of the previous protocols can effectively guide the design and 
refinement of the next generation of candidate vaccines. In this scenario, the perspective is 
that knowledge of the various interdisciplinary areas of science can provide an environment 
leading to overcome these scientific challenges. 
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